NATCO Announces Launch of First Generic Version of Pomalyst® (Pomalidomide) Capsules in the Australian Market
2021-11-09 · NATCO Pharma Ltd. · original natcopharma.co.in ↗
NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce the launch of first generic version of Pomalyst® (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market. The product was launched by NATCO’s commercial partner Juno Pharmaceuticals Pty Ltd. Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma. For more information refer to the full prescribing information or other medical resources. Pomalyst® registered sales of USD 35.6 million in the Australian market for the year ending 31st March 2022 as per industry sales data. Pomalyst ® is a registered trademark of Celgene/BMS. All brand names and trademarks are the property of their respective owners.
The release as fetched from its publisher. natcopharma.co.in ↗